Early reports as far back as 2009 indicated potential involvement of FoxP3+ CD4+ Tregs in the anti-tumour response in patients that had been treated with a MHC II-restricted MAGE-A3 peptide vaccine [18]. Here, MAGEA3 is linked to neoplasm.